Hengrui Pharmaceutical: Hiqu Boapariprofen Ethanolamine Tablets Accepted for Filing

Hengrui Pharmaceuticals announced that recently, the company has received a "Notice of Acceptance" issued by the National Medical Products Administration. The company's drug Haiqu Botpag Itanolamine Tablets has obtained acceptance for its application for drug market authorization from the National Medical Products Administration. The indication is: suitable for adult patients and children aged 6 and above with persistent and chronic primary immune thrombocytopenia who have had poor response to previous treatment with glucocorticoids, immunoglobulins, etc.